Search
  1. Home
  2. Africa

Speedy US approval of cheap AIDS drugs expected

    JOHANNESBURG

    A call by the US administration for the speedy clearance of more generic drugs could see a lot more antiretrovirals (ARVs) included in President Bush's $15 billion global anti-AIDS programme.

    "We have put a lot of effort into hand-holding with generic companies around the world to encourage them, so my guess is in the next few months we will see more drugs included. The first company to apply was approved ... and we expect more," Randall Tobias, coordinator of the US President's Emergency Plan for AIDS Relief (PEPFAR), said in a statement.

    In a move that allows PEPFAR recipients to use the cheaper versions of branded drugs, the Bush Administration last year announced a fast-track scheme for generic ARVs to get US Food and Drug Administration (FDA) approval for safety and quality.

    South Africa's Aspen Pharmacare, recently became the first company to win FDA regulatory approval for its generic anti-AIDS drugs.

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join